Trials / Not Yet Recruiting
Not Yet RecruitingNCT07516015
Clinical Effectiveness and Safety of SHR-A1811 in Chinese Patients With HER2-Altered NSCLC
Clinical Effectiveness and Safety of SHR-A1811 in Chinese Patients With HER2-Altered Advanced/Metastatic Non-small Cell Lung Cancer: a Prospective, Observational Study
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,000 (estimated)
- Sponsor
- Nanjing Tianyinshan Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
SHR-A1811 is an approved therapy for non-small cell lung cancer (NSCLC) in China. Despite the clinical trial evidence, there is no real-world data of SHR-A1811 used in Chinese lung cancer patients with HER2 alteration. This real world, prospective study will assess the effectiveness and safety of SHR-A1811 in patients with locally advanced or metastatic, HER2-Altered NSCLC in real-world setting.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | No Drug | This is an non-interventional, observational study. No drug will be provided or administered as part of this protocol; however, participants on SHR-A1811 will be enrolled in this study. |
Timeline
- Start date
- 2026-04-10
- Primary completion
- 2029-09-30
- Completion
- 2029-12-31
- First posted
- 2026-04-07
- Last updated
- 2026-04-07
Source: ClinicalTrials.gov record NCT07516015. Inclusion in this directory is not an endorsement.